Experts recommendations on RSV and meningitis vaccines go to ex-prosecutor now at CDC
On Apr. 16, 2025, A federal panel of medical experts has recommended an expansion of RSV vaccinations for…
RSV vaccine 78% to 80% effective against infection, severe illness in older US veterans
On Jan. 24, 2025, researchers from the Veterans Affairs Portland Health Care System in Oregon reported results from…
Biotechnology | CDC | COVID-19 | Diagnostics | Infectious Disease | Influenza | Therapeutics | Vaccine
U.S. respiratory virus infections rise, led by flu
On Jan. 3, 2025, the Centers for Disease Control and Prevention (CDC) reported that during Christmas week, respiratory…
Greater Acceptance of RSV Vaccine Seen as Vaccine Hesitancy Appears to Have Plateaued
On Dec. 23, 2024, an Annenberg Public Policy Center (APPC) health survey conducted in November 2024 showed that…
RSV vaccine showed high efficacy for adults 60+
On Dec. 16, 2024, JAMA Network Open published a study demonstrating respiratory syncytial virus (RSV) vaccine effectiveness in adults…
COVID-19 linked to more heart complications than flu, RSV
On Dec. 16, 2024, a study published in BMC Cardiovascular Disorders shows that pediatric and young adult COVID-19…
Biotechnology | CDC | COVID-19 | Diagnostics | FDA | Infectious Disease | Influenza | Measles | Polio | Vaccine
COVID-19 Vaccination Coverage Among U.S. Adults reported below 20%
On Nov. 21, 2024, the U.S. Centers for Disease Control and Prevention (CDC) reported that by the week…
Before RSV vaccine, virus caused substantial illness in US adults
On Nov. 13, 2024, a study published in JAMA Network Open showed that respiratory syncytial virus (RSV) was…
Biotechnology | HIV | Infectious Disease | Medicine | Vaccine | WHO
WHO study lists top endemic pathogens for which new vaccines are urgently needed
On Nov. 5, 2024, a World Health Organization (WHO) study published in eBioMedicine named 17 pathogens that regularly…
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
On Oct. 22, 2024, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO® (Respiratory…
Biotechnology | Diagnostics | Infectious Disease | Medicine | Non-Profit Research | Therapeutics | Vaccine
new data showed Over half of U.S. kids infected with RSV in infancy
On Sept. 19, 2024, a U.S. population-based birth cohort study was released that showed that 53.4% of babies…
RSV vaccine in older people reduced risk of hospitalization
On Sep. 4, 2024, researcher led by the Centers for Disease Control and Prevention (CDC) and Vanderbilt University…
Vaccine Misinformation caused U.S. Covid-19 Vaccination rate to Drop
On Aug. 28, 2024, survey data from the Annenberg Public Policy Center (APPC) found that the number of…
Late-pregnancy RSV vaccination not associated with poor birth outcomes
On Jul. 8, 2024, a study reported that babies exposed to maternal RSV (respiratory syncytial virus) vaccination in…
Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA EUA
On Jun. 10, 2024, Roche announced that the U.S. Food and Drug Administration (FDA) had granted Emergency Use…
Moderna received U.S. FDA approval for RSV vaccine mRESVIA
On May 31, 2024, Moderna announced that the U.S. Food and Drug Administration (FDA) had approved mRESVIA (mRNA-1345),…
Beyfortus approved in China for the prevention of RSV disease in infants
On Jan. 4, 2024, AstraZeneca Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, was approved in China for the…
Upsurge of respiratory illnesses reported among children in Northern China
On Nov. 23, 2023, the World Health Organization (WHO) announced that it was monitoring data from Chinese surveillance…
CDC and FDA expedited availability of additional doses of new RSV immunization for infants
On Nov. 16, 2023, the CDC announced the release of more than 77,000 additional doses of Beyfortusﾙ (nirsevimab-alip…
CDC expanded testing of international air traveler samples to include flu RSV, and other respiratory viruses
On Nov. 6, 2023, the U.S. Centers for Disease Control and Prevention (CDC) announced that it was conducting…
U.S. FDA approved ABRYSVO, Pfizer’s vaccine for prevention of RSV in infants through active immunization of pregnant Individuals
On Aug. 21, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO (Respiratory…
BD received 510(k) clearance for COVID-19, influenza A/B, RSV molecular combination test
On Aug. 1, 2023, BD announced that the U.S. Food and Drug Administration (FDA) 510(k) had provided clearance…
U.S. FDA approved new drug to prevent RSV in babies and toddlers
On Jul. 17, 2023, the FDA approved AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV)…
CDC recommended RSV vaccine for older adults
On Jun. 29, 2023, the Centers for Disease Control and Prevention (CDC) endorsed the CDC Advisory Committee on…
Disease | FDA | Pharmaceutical | Therapeutics | Vaccine
U.S. FDA approved ABRYSVO, Pfizer’s vaccine for prevention of RSV in older adults
On May 31, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO (Respiratory…
Biotechnology | FDA | Therapeutics | Vaccine
U.S. FDA approved first Respiratory Syncytial Virus (RSV) vaccine
On May 3, 2023, the U.S. FDA approved GlaxoSmithKline’s Arexvy as the first respiratory syncytial virus (RSV) vaccine…
Biotechnology | FDA | Therapeutics | Vaccine
U.S. FDA approved PREVNAR 20, Pfizer’s 20-valent pneumococcal conjugate vaccine for infants and children
On Apr. 27, 2023, Pfizer announced that experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing…
Pfizer RSV vaccine 82% effective vs severe infection in infants, final data showed
On Apr. 5, 2023, Pfizer announced that experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing…
Biotechnology | COVID-19 | Diagnostics | FDA | Infectious Disease | Influenza | Vaccine
BD received FDA EUA for COVID-19, influenza A/B, RSV combination test
On Feb. 8, 2023, BD announced that it had received Emergency Use Authorization from the U.S. Food and…
Moderna announced mRNA-1345, an investigational RSV Vaccine, met primary efficacy endpoints in phase 3 trial
On Jan. 17, 2023, Moderna announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of…